Medical Condition News

RSS

Institute of Medicine to be congratulated for calling more resources to fight hypertension

The Institute of Medicine is to be congratulated for sounding the call for more resources to fight hypertension (high blood pressure), the number two preventable cause of death and a leading contributor to heart disease and stroke. Heart disease and stroke are the number one and three overall causes of death of individuals in the United States.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

End-stage ankle arthritis: New treatment options for baby boomers

There's good news for active older adults who are plagued with arthritic ankles. Surgeons presenting today at the American College of Foot and Ankle Surgeons' Annual Scientific Conference in Las Vegas are re-thinking treatment approaches for end-stage ankle arthritis.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Nearly four in 10 transient ischemic attack (TIA) and minor ischemic stroke patients may experience mental impairment, according to a study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Single or unhappily married men may have an elevated risk of fatal stroke in the coming decades, according to a large study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Genetic Disorder Tracker introduced by Guidepoint Global

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease.

25 Feb 2010

More young people are having strokes while older people are having fewer: Study

More young people are having strokes while older people are having fewer, according to data from Ohio and Kentucky presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Researchers develop evaluation tool to help guide asymptomatic pancreatic cyst treatment

As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.

25 Feb 2010

Researchers to test Radio-embolisation technique in patients with bowel cancer

Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy.

24 Feb 2010

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

24 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention.

24 Feb 2010

Meditation improves cognition in people with memory loss

The Alzheimer's Research and Prevention Foundation today announced data demonstrating that a specific meditation performed daily for eight weeks increased brain activity in areas central to memory and actually improved cognition in patients suffering from memory problems. The results of the study, conducted at the University of Pennsylvania, were published in an early online version of an article scheduled to appear in the Journal of Alzheimer's Disease (Volume 20:2, April 2010).

24 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

Incidence rate for all causes of dementia in older people to increase with age: Study

University of California researchers found that the incidence rate for all causes of dementia in people age 90 and older is 18.2% annually and significantly increases with age in both men and women. This research, called "The 90+ Study," is one of only a few to examine dementia in this age group, and the first to have sufficient participation of centenarians.

24 Feb 2010

Observational study on mild demonstrates acute safety of procedure in treatment of LSS

Medical device company Vertos Medical Inc. has reported that an observational study on mild, published in the January/February 2010 issue of the peer-reviewed journal Pain Physician, has demonstrated the acute safety of the procedure in the treatment of lumbar spinal stenosis (LSS).

24 Feb 2010

Lack of knowledge and awareness impeding efforts to control HBV and HCV

A recent report by the Institute of Medicine (IOM) confirmed that 3.5 to 5.3 million people (1-2 % of the U.S. population) have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Despite efforts by federal, state and local government agencies to control and prevent these diseases, they remain a serious public health concern. The major factor impeding efforts to control HBV and HCV is lack of knowledge and awareness among health care providers, social service professionals, members of the public, and policy-makers.

24 Feb 2010

FDA's warning over LABA medications for asthma: AANMA offers guidance

Today Allergy & Asthma Network Mothers of Asthmatics (AANMA) offered guidance to help patients understand recent Food and Drug Administration (FDA) warnings about Advair ® (fluticasone and salmeterol), Foradil ® (formoterol), Severent ® (salmeterol) and Symbicort ® (budesonide and formoterol), daily inhaled medications containing a long-acting beta agonist (LABA, a 12-hour bronchodilator).

24 Feb 2010

Medical Condition News

Institute of Medicine to be congratulated for calling more resources to fight hypertension

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

End-stage ankle arthritis: New treatment options for baby boomers

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Genetic Disorder Tracker introduced by Guidepoint Global

More young people are having strokes while older people are having fewer: Study

Researchers develop evaluation tool to help guide asymptomatic pancreatic cyst treatment

Researchers to test Radio-embolisation technique in patients with bowel cancer

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

Meditation improves cognition in people with memory loss

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Shire receives FDA Fast Track designation for REPLAGAL

Incidence rate for all causes of dementia in older people to increase with age: Study

Observational study on mild demonstrates acute safety of procedure in treatment of LSS

Lack of knowledge and awareness impeding efforts to control HBV and HCV

FDA's warning over LABA medications for asthma: AANMA offers guidance

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News